---
schema_version: "secwatch.filing_event.v1"
accession: "0001127537-21-000045"
form_type: "8-K"
ticker: "LUNG"
cik: "0001127537"
company_name: "Pulmonx Corp"
filed_at: "2021-11-02T23:59:59+00:00"
generated_at: "2026-06-28T14:53:51.445178+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Pulmonx Q3 revenue $13.3M (+25% YoY); net loss $10.2M; maintains FY guidance $49-51M

## Summary
- Worldwide revenue $13.3M, up 25% YoY ($10.6M Q3 2020); U.S. revenue $6.9M (+28%), international $6.4M (+22%).
- Gross margin improved to 73% (70% prior year); net loss $10.2M ($0.28 loss per share) vs $3.9M ($1.37 loss per share).
- Added 18 new U.S. Zephyr Valve treating centers (total 198); positive coverage decisions from Anthem, BCBS Michigan, Horizon NJ (~44M covered lives).
- Cash, cash equivalents, and marketable securities totaled $202.6M as of September 30, 2021.
- Maintains FY 2021 revenue guidance $49-51M; expects near low end due to COVID headwinds; operating expenses guided $83-85M.

## SEC filing metadata
- accession: 0001127537-21-000045
- form_type: 8-K
- ticker: LUNG
- cik: 0001127537
- company_name: Pulmonx Corp
- filed_at: 2021-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1127537/000112753721000045/0001127537-21-000045-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1127537/000112753721000045/lung-20211102.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001127537-21-000045
- JSON: https://secwatch.observer/filing/0001127537-21-000045.json
- Plain text: https://secwatch.observer/filing/0001127537-21-000045.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.